tiziana-logo.png
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23 avr. 2024 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
08 janv. 2024 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
ideaPoint and WideTr
ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines
31 mars 2020 07h00 HE | Anaqua
BOSTON, March 31, 2020 (GLOBE NEWSWIRE) -- Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, today announced a strategic partnership with clinical data company...
Spend on HEOR Studies Expected to Grow at 9.7% Through 2020
19 juil. 2016 10h30 HE | Industry Standard Research
CARY, NC--(Marketwired - July 19, 2016) - Industry Standard Research has released a new report, "Late Phase Study Trends and Market Outlook (2016-2020)," containing findings focused on current...